250 related articles for article (PubMed ID: 21961001)
1. Utility of vascular endothelial growth factor inhibitors in the treatment of ovarian cancer: from concept to application.
Amini A; Masoumi Moghaddam S; Morris DL; Pourgholami MH
J Oncol; 2012; 2012():540791. PubMed ID: 21961001
[TBL] [Abstract][Full Text] [Related]
2. Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
Navone SE; Guarnaccia L; Cordiglieri C; Crisà FM; Caroli M; Locatelli M; Schisano L; Rampini P; Miozzo M; La Verde N; Riboni L; Campanella R; Marfia G
World Neurosurg; 2018 Dec; 120():e380-e391. PubMed ID: 30144594
[TBL] [Abstract][Full Text] [Related]
3. Potential anti-vascular endothelial growth factor therapies for central retinal vein occlusion.
Figueroa MS; Contreras I
Drugs; 2012 Nov; 72(16):2063-71. PubMed ID: 23061805
[TBL] [Abstract][Full Text] [Related]
4. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
Virgili G; Parravano M; Evans JR; Gordon I; Lucenteforte E
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD007419. PubMed ID: 30325017
[TBL] [Abstract][Full Text] [Related]
5. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study.
Gotlieb WH; Amant F; Advani S; Goswami C; Hirte H; Provencher D; Somani N; Yamada SD; Tamby JF; Vergote I
Lancet Oncol; 2012 Feb; 13(2):154-62. PubMed ID: 22192729
[TBL] [Abstract][Full Text] [Related]
6. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
Virgili G; Parravano M; Evans JR; Gordon I; Lucenteforte E
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007419. PubMed ID: 28639415
[TBL] [Abstract][Full Text] [Related]
7. Experience with bevacizumab in the management of epithelial ovarian cancer.
Burger RA
J Clin Oncol; 2007 Jul; 25(20):2902-8. PubMed ID: 17617521
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites.
Colombo N; Mangili G; Mammoliti S; Kalling M; Tholander B; Sternas L; Buzenet G; Chamberlain D
Gynecol Oncol; 2012 Apr; 125(1):42-7. PubMed ID: 22112608
[TBL] [Abstract][Full Text] [Related]
9. Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer.
Masoumi Moghaddam S; Amini A; Morris DL; Pourgholami MH
Cancer Metastasis Rev; 2012 Jun; 31(1-2):143-62. PubMed ID: 22101807
[TBL] [Abstract][Full Text] [Related]
10. Malignant ascites in ovarian cancer and the role of targeted therapeutics.
Smolle E; Taucher V; Haybaeck J
Anticancer Res; 2014 Apr; 34(4):1553-61. PubMed ID: 24692682
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model.
Byrne AT; Ross L; Holash J; Nakanishi M; Hu L; Hofmann JI; Yancopoulos GD; Jaffe RB
Clin Cancer Res; 2003 Nov; 9(15):5721-8. PubMed ID: 14654557
[TBL] [Abstract][Full Text] [Related]
12. Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema.
Jampol LM; Glassman AR; Liu D; Aiello LP; Bressler NM; Duh EJ; Quaggin S; Wells JA; Wykoff CC;
Ophthalmology; 2018 Jul; 125(7):1054-1063. PubMed ID: 29525602
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
Teoh D; Secord AA
Int J Gynecol Cancer; 2012 Mar; 22(3):348-59. PubMed ID: 22266932
[TBL] [Abstract][Full Text] [Related]
14. Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes.
MacDonald DA; Martin J; Muthusamy KK; Luo JK; Pyles E; Rafique A; Huang T; Potocky T; Liu Y; Cao J; Bono F; Delesque N; Savi P; Francis J; Amirkhosravi A; Meyer T; Romano C; Glinka M; Yancopoulos GD; Stahl N; Wiegand SJ; Papadopoulos N
Angiogenesis; 2016 Jul; 19(3):389-406. PubMed ID: 27234973
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT.
Hykin P; Prevost AT; Sivaprasad S; Vasconcelos JC; Murphy C; Kelly J; Ramu J; Alshreef A; Flight L; Pennington R; Hounsome B; Lever E; Metry A; Poku E; Yang Y; Harding SP; Lotery A; Chakravarthy U; Brazier J
Health Technol Assess; 2021 Jun; 25(38):1-196. PubMed ID: 34132192
[TBL] [Abstract][Full Text] [Related]
16. Current status on biologic therapies in the treatment of epithelial ovarian cancer.
Han ES; Lin P; Wakabayashi M
Curr Treat Options Oncol; 2009 Apr; 10(1-2):54-66. PubMed ID: 19381822
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of aflibercept in the treatment of metastatic colorectal cancer.
Macarulla T; Sauri T; Tabernero J
Expert Opin Biol Ther; 2014 Oct; 14(10):1493-505. PubMed ID: 25152076
[TBL] [Abstract][Full Text] [Related]
18. Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial.
Zhao H; Li X; Chen D; Cai J; Fu Y; Kang H; Gao J; Gao K; Du N
Med Oncol; 2015 Feb; 32(2):292. PubMed ID: 25609006
[TBL] [Abstract][Full Text] [Related]
19. Markedly elevated levels of vascular endothelial growth factor in malignant ascites.
Zebrowski BK; Liu W; Ramirez K; Akagi Y; Mills GB; Ellis LM
Ann Surg Oncol; 1999 Jun; 6(4):373-8. PubMed ID: 10379858
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab in the treatment of ovarian cancer.
Eskander RN; Randall LM
Biologics; 2011; 5():1-5. PubMed ID: 21383911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]